Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 May 1.

Published in final edited form as: Pain. 2010 Mar 4;149(2):254–262. doi: 10.1016/j.pain.2010.02.009

Mean percent change in PWT of cancer-inoculated animals injected with a ten-fold magnitude range of nonspecific opioid receptor (OR) antagonist, naloxone methiodide, either in the cancer or into the contralateral paw. (a) 500 μg/kg naloxone methiodide (n = 10) administered into the cancer paw of animals significantly reduced mean PWT compared to PBS (n = 10) and lower concentrations at 5 and 50 μg/kg (n = 10, each group) at t = 15 min after drug injection, lasting up to 1 hr post-injection (p < 0.05). [* denotes statistical significance] (b) 5 μg/kg (n = 5), 50 μ/kg (n = 5), and 500 μg/kg (n = 10) of naloxone methiodide administered into the contralateral hind paw has no effect on mean PWT compared to PBS (n = 10) injected into the cancer paw of animals

Mean percent change in PWT of cancer-inoculated animals injected with a ten-fold magnitude range of nonspecific opioid receptor (OR) antagonist, naloxone methiodide, either in the cancer or into the contralateral paw. (a) 500 μg/kg naloxone methiodide (n = 10) administered into the cancer paw of animals significantly reduced mean PWT compared to PBS (n = 10) and lower concentrations at 5 and 50 μg/kg (n = 10, each group) at t = 15 min after drug injection, lasting up to 1 hr post-injection (p < 0.05). [* denotes statistical significance] (b) 5 μg/kg (n = 5), 50 μ/kg (n = 5), and 500 μg/kg (n = 10) of naloxone methiodide administered into the contralateral hind paw has no effect on mean PWT compared to PBS (n = 10) injected into the cancer paw of animals